News Release

Oncorus to Participate in Upcoming Investor Conferences

November 23, 2022 at 8:00 AM EST

ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences:

  • Evercore ISI 5th Annual HealthCONx Conference: Virtual fireside chat on Thursday, December 1, 2022 at 10:55 a.m. ET.
  • Piper Sandler 34th Annual Healthcare Conference: Fireside chat on Thursday, December 1, 2022 at 12:30 p.m. ET in New York, NY.

A webcast of each event can be accessed by visiting the Investors & Media section of Oncorus’ website at A replay of the webcast will be archived on Oncorus’ website for 90 days following the event.

About Oncorus

At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to stimulate the immune system and transform outcomes for cancer patients. We are advancing a portfolio of intratumorally (iTu) and intravenously (IV) administered viral immunotherapies for multiple indications with significant unmet need based on our Herpes Simplex Virus (HSV) and self-amplifying viral RNA/LNP Platforms.

Designed as a next-generation viral immunotherapy, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity with immune stimulating payloads. Our lead HSV program, ONCR-177, currently in the clinic, is designed to be directly administered into a tumor, resulting in high local concentrations of therapeutic agent and its five encoded transgenes, as well as low systemic exposure to the therapy, which could limit systemic toxicities. Our pioneering self-amplifying vRNA/LNP Platform, highlighted by our product candidates ONCR-021 and ONCR-788, involves a highly innovative, novel combination of RNA and LNP-based modalities designed to realize the potential of RNA medicines for cancer.

Please visit to learn more.

Investor Contact:
Stern Investor Relations
Julie Seidel